ZBH

Zimmer Biomet Holdings, Inc. (ZBH) | Rumor.io

Zimmer Biomet Holdings

ZBH

Attention (50-day avg)0%

Attention rank (50-day avg)#2,885

Bullish sentiment (50-day avg)92%

Price to earnings ratio22.2

Market capitalization17.5B

Earnings per share4.12

Dividend yield (TTM)1.05%

Revenue (annual)8.2B

Net income (annual)705.1M

Social

What share of all stock conversation is about ZBH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Apr 28

Zimmer Biomet Holdings reports Q1 2026 earnings, with EPS missing estimates and revenue exceeding expectations.
The company raises its full-year 2026 adjusted diluted EPS guidance to $8.40 to $8.55, and also raises free cash flow expectations.
Zimmer Biomet CFO Suketu Upadhyay is departing the company, creating uncertainty and prompting investors to manage risk around key levels.

Generated by AI

Sentiment

Of the messages about ZBH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	25% -75	89.63% -6.46
Bearish	—	—	75% new	10.37% +6.46

Bullish· Sep 7

Zimmer Biomet Holdings, Inc. (ZBH) is poised to break out of its current downtrend due to its undervalued status compared to trendy tech and AI industries.
ZBH has a strong position in the musculoskeletal care market, with a potential for growth as it becomes a more attractive investment option.
Despite being compared to industry leader Stryker, ZBH has a solid business quality and could be a worthwhile investment for those looking for a value opportunity.

Bearish· Oct 31

Zimmer Biomet Holdings, Inc. cut guidance by 1%, resulting in a 14% stock price drop.
The company's comment on the tele-rehab acquisition was seen as negative, making the stock uncomfortable for even short sellers.
Zimmer Biomet's supply chain issues, rather than demand, were cited as a reason for the company's decline, despite a long-term trend of increasing hip and knee replacements.

Generated by AI

Topics

Of the messages about ZBH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	4.39%
Technical Analysis	—	—	0%	0.55%
Earnings	—	—	100%	2.56%
Analysts	—	—	0%	88.77%
Macro	—	—	0%	3.66%
Controversies	—	—	0%	0.07%

Earnings· Feb 7

Zimmer Biomet Holdings, Inc. (ZBH) reported quarterly earnings of $1.95 per share, missing consensus estimates by 3 cents a share.
Revenue came in short of analysts' forecasts at $2.04 billion, missing estimates by $30 million.
The company provided weak FY22 guidance, with EPS expected to be below consensus and revenue expected to be below consensus.

Analysts· Feb 8

Zimmer Biomet Holdings, Inc. ($ZBH) has received various price target updates and downgrades from analysts, with targets ranging from $110 to $165.
Several analysts have lowered their price targets for $ZBH, including SVB Leerink, Canaccord Genuity Group, and Needham & Company LLC.
Analysts maintain a mixed outlook for $ZBH, with some maintaining a Buy or Outperform rating and lowering their price targets, while others have downgraded the stock to Hold.

Announcements· Jul 14

Zimmer Biomet Holdings ($ZBH) will acquire Monogram Technologies ($MGRM) for $4.04 per share in cash, totaling $177 million, and an enterprise value of $168 million.
The acquisition will add autonomous robotics technology to Zimmer Biomet's ROSA platform, with potential to become the first company with fully autonomous surgical robots in orthopedics.
Monogram Technologies shareholders will also receive a non-tradeable contingent value right (CVR) of up to $12.37 per share if certain milestones are achieved through 2030.

Macro· Jan 31

The US Department of Energy (DOE) is involved in a cooperative agreement to enable the development of electric vehicle contracts with Microvast, GM, and Ford.
The government's involvement in this agreement suggests a potential shift towards broader scale vehicle electrification in the USA.
Programs like this are critical to advancing the technology needed to meet both near- and long-term goals for vehicle electrification, according to Steve Zimmer, executive director of USCAR.

Generated by AI

Community

Of the messages about ZBH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	23.08%	16.32%
Newcomers	—	100%	76.92%	83.68%

Regulars· Nov 5

Zimmer Biomet reports Q3 2025 earnings, with revenue increasing 9.7% due to M&A, but GAAP profitability declining.
The company's Q3 revenue surge is attributed to successful innovation and sales growth in knees, but misexecution in non-core areas hurts organic growth.
Zimmer Biomet's share price has dropped 16% due to shareholder frustration, with long-term investors hoping for innovation to accelerate sales and address share losses.

Newcomers· Aug 7

$ZBH is a high-margin medtech company with a P/E ratio of 11x, which some view as a positive attribute.
The company's Q2 FY2025 earnings report was strong, with adjusted EPS beating estimates and full-year EPS guidance raised.
The report's success may lead to a post-earnings run, with some users speculating that the stock price could reach $105.

Generated by AI

Zimmer Biomet currently trades at $91.50 per share and has shown little upside over the past six months, posting a middling return of 4.4%. The stock also fell short of the S&P 500’s 16.9% gain during that period.

4d agoYahoo Finance

Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day

4d agoMarketWatch

Zimmer Biomet Holdings (ZBH) Pushes Cost Reset Plans, Is It Still 17% Below Fair Value?

Zimmer Biomet Holdings: recent performance and context Zimmer Biomet Holdings (ZBH) has drawn investor attention after a stretch of weaker share performance, with the stock down 1.3% over the past day and 10.5% over the past month. At a share price of US$89.69, Zimmer Biomet Holdings has seen momentum fade recently, with the 30-day share price return down 10.5% and the 1-year total shareholder return declining 6.5%. This points to cooler sentiment following earlier periods of...

4d agoYahoo Finance

Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know

A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.

6d agoYahoo Finance

Minimally Invasive Robotic Surgical System Market Global Report 2026: Benchmark Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker and Zimmer Biomet Now

Players: Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker, Zimmer Biomet. Profile covers competitors, segments, regional shares, trends and opportunities. Minimally Invasive Robotic Surgical System Market Minimally Invasive Robotic Surgical System Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Minimally Invasive Robotic Surgical System Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Minimally Invasive Robotic Surgical System Market to Reach $18.15 Bil

7d agoYahoo Finance UK

Also Discussed

Investors talking about ZBH also mention

#	Name	Attention
1	Stryker CorporationSYK	0.01%+0.01
2	Smith & Nephew plc Sponsored ADRSNN	0%new
3	NUVA - NuVasive, Inc.	——
4	America First Multifamily Investors LPATAX	0%0
5	Boston Scientific Corp.BSX	0.03%-0.02
6	CDW Corp-DECDW	0%0
7	Amerant Bancorp Inc.AMTB	0%0
8	Omega Flex Inc.OFLX	0%new
9	CONMED CorporationCNMD	0%new
10	New Jersey Resources CorporationNJR	0%0

Zimmer Biomet Holdings, Inc.

Healthcare
Medical Devices

Zimmer Biomet Holdings, Inc. is a medical device company specializing in musculoskeletal healthcare solutions. The company designs, manufactures, and markets orthopedic reconstructive implants for hips, knees, and shoulders, along with a broad range of products for sports medicine, extremities, and trauma surgery. Its portfolio also includes surgical tools, biologics, and digital and robotic technologies that support orthopedic procedures and post-operative care. Zimmer Biomet serves hospitals, ambulatory surgery centers, and healthcare professionals worldwide, focusing on products that enable joint replacement, bone repair, and improved mobility for patients. Following the spin-off of its dental and spine businesses, the company is concentrated on large joint reconstruction and related musculoskeletal products as core areas of activity. Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet holds a significant position in the global orthopedic market, particularly in the United States, Europe, and Japan, where it is a key supplier to orthopedic surgeons and healthcare systems.

Website

Location

345 East Main Street

Warsaw, IN, 46580

United States

Social

What share of all stock conversation is about ZBH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Apr 28

Zimmer Biomet Holdings reports Q1 2026 earnings, with EPS missing estimates and revenue exceeding expectations.
The company raises its full-year 2026 adjusted diluted EPS guidance to $8.40 to $8.55, and also raises free cash flow expectations.
Zimmer Biomet CFO Suketu Upadhyay is departing the company, creating uncertainty and prompting investors to manage risk around key levels.

Generated by AI

Sentiment

Of the messages about ZBH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	25% -75	89.63% -6.46
Bearish	—	—	75% new	10.37% +6.46

Bullish· Sep 7

Zimmer Biomet Holdings, Inc. (ZBH) is poised to break out of its current downtrend due to its undervalued status compared to trendy tech and AI industries.
ZBH has a strong position in the musculoskeletal care market, with a potential for growth as it becomes a more attractive investment option.
Despite being compared to industry leader Stryker, ZBH has a solid business quality and could be a worthwhile investment for those looking for a value opportunity.

Bearish· Oct 31

Zimmer Biomet Holdings, Inc. cut guidance by 1%, resulting in a 14% stock price drop.
The company's comment on the tele-rehab acquisition was seen as negative, making the stock uncomfortable for even short sellers.
Zimmer Biomet's supply chain issues, rather than demand, were cited as a reason for the company's decline, despite a long-term trend of increasing hip and knee replacements.

Generated by AI

Topics

Of the messages about ZBH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	4.39%
Technical Analysis	—	—	0%	0.55%
Earnings	—	—	100%	2.56%
Analysts	—	—	0%	88.77%
Macro	—	—	0%	3.66%
Controversies	—	—	0%	0.07%

Earnings· Feb 7

Zimmer Biomet Holdings, Inc. (ZBH) reported quarterly earnings of $1.95 per share, missing consensus estimates by 3 cents a share.
Revenue came in short of analysts' forecasts at $2.04 billion, missing estimates by $30 million.
The company provided weak FY22 guidance, with EPS expected to be below consensus and revenue expected to be below consensus.

Analysts· Feb 8

Zimmer Biomet Holdings, Inc. ($ZBH) has received various price target updates and downgrades from analysts, with targets ranging from $110 to $165.
Several analysts have lowered their price targets for $ZBH, including SVB Leerink, Canaccord Genuity Group, and Needham & Company LLC.
Analysts maintain a mixed outlook for $ZBH, with some maintaining a Buy or Outperform rating and lowering their price targets, while others have downgraded the stock to Hold.

Announcements· Jul 14

Zimmer Biomet Holdings ($ZBH) will acquire Monogram Technologies ($MGRM) for $4.04 per share in cash, totaling $177 million, and an enterprise value of $168 million.
The acquisition will add autonomous robotics technology to Zimmer Biomet's ROSA platform, with potential to become the first company with fully autonomous surgical robots in orthopedics.
Monogram Technologies shareholders will also receive a non-tradeable contingent value right (CVR) of up to $12.37 per share if certain milestones are achieved through 2030.

Macro· Jan 31

The US Department of Energy (DOE) is involved in a cooperative agreement to enable the development of electric vehicle contracts with Microvast, GM, and Ford.
The government's involvement in this agreement suggests a potential shift towards broader scale vehicle electrification in the USA.
Programs like this are critical to advancing the technology needed to meet both near- and long-term goals for vehicle electrification, according to Steve Zimmer, executive director of USCAR.

Generated by AI

Community

Of the messages about ZBH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	23.08%	16.32%
Newcomers	—	100%	76.92%	83.68%

Regulars· Nov 5

Zimmer Biomet reports Q3 2025 earnings, with revenue increasing 9.7% due to M&A, but GAAP profitability declining.
The company's Q3 revenue surge is attributed to successful innovation and sales growth in knees, but misexecution in non-core areas hurts organic growth.
Zimmer Biomet's share price has dropped 16% due to shareholder frustration, with long-term investors hoping for innovation to accelerate sales and address share losses.

Newcomers· Aug 7

$ZBH is a high-margin medtech company with a P/E ratio of 11x, which some view as a positive attribute.
The company's Q2 FY2025 earnings report was strong, with adjusted EPS beating estimates and full-year EPS guidance raised.
The report's success may lead to a post-earnings run, with some users speculating that the stock price could reach $105.

Generated by AI

Zimmer Biomet Holdings

Social

Apr 28

Bullish· Sep 7

Bearish· Oct 31

Earnings· Feb 7

Analysts· Feb 8

Announcements· Jul 14

Macro· Jan 31

Regulars· Nov 5

Newcomers· Aug 7

BMO reiterates Zimmer Biomet stock rating on Japan hip implant opportunity

Zimmer Biomet (ZBH): Buy, Sell, or Hold Post Q2 Earnings?

Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day

Zimmer Biomet Holdings (ZBH) Pushes Cost Reset Plans, Is It Still 17% Below Fair Value?

Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know

Minimally Invasive Robotic Surgical System Market Global Report 2026: Benchmark Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker and Zimmer Biomet Now

Also Discussed

Zimmer Biomet Holdings, Inc.

Company Information

Location

BMO reiterates Zimmer Biomet stock rating on Japan hip implant opportunity

Zimmer Biomet (ZBH): Buy, Sell, or Hold Post Q2 Earnings?

Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day

Zimmer Biomet Holdings (ZBH) Pushes Cost Reset Plans, Is It Still 17% Below Fair Value?

Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know

Minimally Invasive Robotic Surgical System Market Global Report 2026: Benchmark Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker and Zimmer Biomet Now

Also Discussed

Social

Apr 28

Bullish· Sep 7

Bearish· Oct 31

Earnings· Feb 7

Analysts· Feb 8

Announcements· Jul 14

Macro· Jan 31

Regulars· Nov 5

Newcomers· Aug 7